These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 29409124)

  • 1. Current developments in immunotherapy in the treatment of multiple myeloma.
    Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
    Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
    Minnie SA; Hill GR
    Front Immunol; 2021; 12():651288. PubMed ID: 33777050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
    Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T cell therapies for multiple myeloma.
    Wu C; Zhang L; Brockman QR; Zhan F; Chen L
    J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
    Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy.
    Rocchi S; Zannetti BA; Marconi G; Lanza F
    Cells; 2024 May; 13(10):. PubMed ID: 38786075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
    Feinberg D; Paul B; Kang Y
    Cell Immunol; 2019 Nov; 345():103964. PubMed ID: 31492448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].
    ; ;
    Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):341-346. PubMed ID: 32370461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
    Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is autologous stem cell transplantation still relevant for multiple myeloma?
    Choi T
    Curr Opin Hematol; 2019 Nov; 26(6):386-391. PubMed ID: 31567432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immunotherapy in multiple myeloma.
    Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
    Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
    Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Fang HB; Cai L; Janofsky S; Chew A; Storek J; Akpek G; Badros A; Yanovich S; Tan MT; Veloso E; Pasetti MF; Cross A; Philip S; Murphy H; Bhagat R; Zheng Z; Milliron T; Cotte J; Cannon A; Levine BL; Vonderheide RH; June CH
    Blood; 2011 Jan; 117(3):788-97. PubMed ID: 21030558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
    Pianko MJ; Moskowitz AJ; Lesokhin AM
    Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Attal M; Harousseau JL
    Baillieres Best Pract Res Clin Haematol; 1999; 12(1-2):171-91. PubMed ID: 11000991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.
    Wang L; Yao R; Zhang L; Fan C; Ma L; Liu J
    Int Immunopharmacol; 2019 May; 70():498-503. PubMed ID: 30875561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tandem stem cell transplantation for multiple myeloma patients.
    Martino M; Recchia AG; Fedele R; Neri S; Vincelli ID; Moscato T; Gentile M; Morabito F
    Expert Opin Biol Ther; 2016; 16(4):515-34. PubMed ID: 26698133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.